Keith Speights: All right, Brian. In this year's M&A deals, most of the acquisition targets were those that were involved in developing cancer drugs or gene therapies. Fun fact: the company was named after Alnilam, the central star of Orions belt and the spelling was slightly modified to make it unique. Article printed from InvestorPlace Media, https://investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. That's right -- they think these 10 stocks are even better buys. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. quotes delayed at least 15 minutes, all others at least 20 minutes. The following seven biotech stocks could end up as M&A targets in 2022: Alnylam (NASDAQ:ALNY) may have faced a setback recently following an extension to the review period for its Vutisiran, a next-gen RNAi therapeutic candidate, but it still has one of the most exciting pipelines. Global Blood Therapeutics ( GBT) - $9B. The pipeline progress has been encouraging. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. There were a few, but not as many. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Total consideration can reflect both cash and equity offered upfront in exchange for the acquired companys shares, but deals in which the upfront payment was not specified, or was less than $50 million, were not included. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . (2016). Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Just briefly, very quickly, I think Biogen (BIIB 0.54%) needs to make an acquisition -- ticker for Biogen is BIIB. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. earnings call is. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. The quest behind the drive is to fill potential gaps in the pipeline. 1, I would love to see any of the biotech stocks that I own be acquired, for the right price obviously. In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss potential biotech buyouts that would be great for investors. Licensed from Palatin Technologies Inc., the first-in-class melanocortin-4 receptor agonist is thought to offer . Specifically, Seagen has an anti-TIGIT antibody. While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. Company CEO Paul Wotton stated in the Antares 2nd quarter earnings call in 2012 that Pfizer approached Antares because it had a product on its shelf for three years which Antares might be able to help develop. 2019 saw more than 25 acquisition deals executed in the biotech sector, of which 14 were billion-dollar deals. Alexion Pharmaceuticals. CRISPR has a licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals worth more than a $900 million for this program. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Keith Speights: Let's switch gears. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." Keith Speights owns Bristol Myers Squibb and Vertex Pharmaceuticals. Myovant Science is a small pharmaceutical company with offices in Brisbane (California) and Basel (Switzerland) focusing on the development and commercialization of innovative therapies for womens and mens health diseases and other endocrine-related disorders. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. Merger and acquisition activity has been rather slow in the biopharma industry so far this year. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. In Voce's recent letters to Solta, it has identified at least three parties that are interested in acquiring Solta now, so I expect the pressure to continue to heat up and eventually boil over into an acquisition of the company. And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . Markets. We expect approval for ValRox in Europe and the U.S. in the next few months. Best Penny Stocks . Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. I originally heard in March of last year that AcelRx was being "shopped around" when the stock was trading under $5 a share. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Subscribe to BioPharma Dive. Best Stocks & ETFs. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Price as of January 17, 2023, 4:00 p.m. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Enclose phrases in quotes. Targeted indications include cardio-renal, metabolic, neurological, infectious diseases, cancer, ophthalmology, pulmonary & allergy and hematology. Making the world smarter, happier, and richer. Invest better with The Motley Fool. One of the hot topics in the biopharmaceutical world are mergers & acquisitions (M&A). Dealmaking is essential to the business of drug development. Sold Pharsight Corporation to Tripos International: Mr. Rosen served on the Board of Directors of Pharsight Corporation. However, there is no way to know for sure since I'm not an insider and have no inside information. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. The buyout rumors got reignited last month when Novartis (NVS) agreed to acquire The Medicines Co., which is developing Inclisiran, a drug for heart disease, for $9.7 billion. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. We first began to hear acquisition rumors in Antares in late 2011. 06-01-2023. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. We at Biotech Investments expect that pace to continue for the remainder of 2022. In case of a buyout, investors often benefit of a massive premium. Speights: Now, Brian, I'm going to agree with you on every point you just made. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. Well, first, I am a shareholder of both Vertex and Bristol-Myers Squibb, so I like your ideas there. For this story, BioPharma Dive looked only at companies developing human medicines. Alnylam stock has a market capitalization of over $20 billion. 8. Merger and acquisitions (M&A) have been tepid so far in 2020 following a blockbuster 2019, which witnessed two mega-merger deals . Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Any you had ideas about? Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. Who will buy? Below are the most notable members and their respective acquisition activity: 1. Today, I will cover some companies that I have been following and hearing some rumors on. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. It was also approved in the EU. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . Vertex could also be an attractive buyout target for a big pharma company. The Motley Fool recommends Biogen and Gilead Sciences. CRISPRs lead product candidate, CTX001, is an investigational, autologous, gene-edited hematopoietic stem cell therapy that is being evaluated for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. One of leaders in this field is CRISPR Therapeutics, a Cambridge (MA)-based biopharmaceutical company focused on the discovery and development of transformative genetic medicines for serious human diseases such as hemoglobinopathies, diabetes, or cancer. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Want the latest recommendations from Zacks Investment Research? Are some major acquisitions on the way in the biopharmaceutical industry this year? I wrote this article myself, and it expresses my own opinions. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. RTTNews->. We believe the above track record is very telling about the future of AcelRx, and leads further validity to the rumors we have been hearing regarding a possible acquisition of the company. . Price as of January 17, 2023, 4:00 p.m. "Human natural killer cell" [Micrograph]. The Motley Fool has a disclosure policy. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo. Biogen and Gilead Sciences would also do well to make some M&A deals this year. The companys drug Ocaliva has been approved for primary biliary cholangitis. 5. Sales of Vascepa have been growing, and in October of this year, an independent drug price watchdog group, Institute for Clinical and Economic Review (ICER), released a report that shows Vascepa as cost-effective for CV risk reduction. However, the Company has turned down Elliott's recommendation. Want to Get Richer? Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Example: +water -Europe Clovis Oncology shares have gained 270% since November, and trade around $13. Pharma giant Pfizer recently. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Ra Medical Systems (NYSE American: RMED) announces a realignment of its board of directors in conjunction with the recently announced merger with Catheter Precision, Inc. David Jenkins has joined the board as Executive Chairman and James Caruso has been named director. There would be some synergies on the commercial sales side. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. BioSpace is covering all the key announcements all week. After a lengthy drought, could biotech M&A be on the upswing? Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. It could find some synergies in having salespeople sell just the same set of drugs from both companies. I took a look at Jack's history as an executive and found some interesting information; It seems to me that Jack was hired as a "bird dog" so to speak - to help develop the company and get it ready for an acquisition at some point. ALXN is down 22% from its all-time high of $141.86, recorded on April 10, 2019, and trades around $110. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. Keep track of M&A as it happens with this database. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Always do your own due diligence before buying and selling any stock, and/or consult with a licensed financial adviser. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. We'll see if that happens, but I think it would be one of the top megamerger acquisition candidates that are on the market right now. The uptake of all these products has been good. I think that would potentially drive sales of Opdivo. 9. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Sanofi has been quite active on the M&A front this year. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges. These gene-based medicines promise potential and make CRISPR an attractive candidate for a potential buyout. ATRS. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). The best transactions benefit the shareholders of both the acquiring company and the takeover target. Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). To make the world smarter, happier, and richer. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. Use a + to require a term in results and - to exclude terms. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. We at Biotech Investments think that the combination of a strong product portfolio generating immediate revenues, an impressive research pipeline as well as the knowhow to successfully launch new treatments ranks BioMarin high on the wish list of many big pharmaceutical companies. Disclosure: I am long ATRS, SLTM, ACRX. According to Glenn Hunzinger, U.S. Pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. BioPharma Dive is tracking these deals below. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Therefore, there are always lots of buyout rumors in the news about potential biotech takeover targets. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. product. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. Additionally, Dan is a Scientist and inventor. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. I don't know, maybe they could out-license those. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Adaptimmune ADAP, a clinical-stage biopharmaceutical company, is focused on the development of novel cancer immunotherapy products. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. Later, Bristol-Myers Squibb for $2.4B. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. Dear MULN Stock Fans, Brace Yourself for a Reverse Stock Split, 5 Under-the-Radar Penny Stocks With 100% Upside Potential, 3 Stocks Set to Soar When the Bears Get Short-Squeezed, 3 Troubled Tech Stocks to Buy For The Long Haul, 3 AI Stocks That Will Make You Amazingly Rich in 10 Years, Attractive & promising pipeline/technology. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Rubraca competes with other PARP inhibitors like Lynparza and Zejula. 1125 N. Charles St, Baltimore, MD 21201. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. If the letter of intent to acquire your company has been signed, you might be asking what happens next. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. Other approved drugs in the companys portfolio continue to do well. Copyright 2023 InvestorPlace Media, LLC. All rights reserved. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. Cost basis and return based on previous market day close. This conference call is no longer online, but the. Retrieved from, New AAPS-RX Global Collaboration Produces 2-for-1 Registration Deal, From American Association of Pharmaceutical Scientists, Vivera Expands TABMELT Global Licensing Reach with Grant of Israel Patent, Former Bayer Executive Jeff Owoc Joins Adapt Ideations, By Jacob Bell, Ben Fidler and Jonathan Gardner, By signing up to receive our newsletter, you agree to our, Centerview grows role as go-to adviser for biopharma dealmaking. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. Healthcare. RTTNews.com for The company is also developing CRISPR gene-editing therapeutic candidates for DMD. I am not receiving compensation for it. . But that deadline has long passed. That remains to be seen. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. Some have merit and turn out to be true, while others turn out to be false and without merit. 11. 10. Analysts, on average, predict over 75% upside for Crispr shares. The company continues to bleed money, and in 2021, it incurred a loss per share of 35 cents per share. Learn More. Copy and paste multiple symbols separated by spaces. , all others at least 20 minutes technology, complementing Sanofis existing &... Fairly lively in 2020 despite a somewhat subdued start: Now, 3 biopharma that. & a ) have been following and hearing some strong acquisition rumors news. Robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications hope happen! Takeover Targets $ 15 billion range its Artificial Intelligence with acquisition of this year continued emergence has fueled..., limb-girdle muscular dystrophies and several other indications by TipRanks agonist is thought to.... Rumors died down after Novartis announced in early January another collaboration with alnylam for developing therapies. Celgene for $ 74 billion in January remains the most notable members and their continued emergence has helped fueled research... The next few months way to know for sure since I 'm going agree. Copyright biotech Investments 2022 | Switzerland | all rights reserved also developing CRISPR gene-editing therapeutic candidates for.... World are mergers & acquisitions ( M & amp ; a activity looks... Be potential acquisition Targets in 2021 always lots of buyout rumors in Antares late! Rights reserved is essential to the business of drug development quite a few, but the Antares 3rd 2012... Public information, I believe each acquisition rumor mentioned here has strong merit incurred loss... Have been snapped by big pharmaceutical companies seen a modest rebound after a slow start, and it expresses own... Rumors died down after Novartis announced in early January another collaboration with alnylam for developing targeted to... Be acquired at some point companys drug Ocaliva has been approved for primary cholangitis! Suggests the S & P 500 Could Soar in 2023 industry so far this year per share a! Promises roughly 35 % upside from current biotech acquisition rumors, based on previous market close... The Antares 3rd quarter 2012 earnings call is Sciences Consulting Solutions Leader at.... December 2011 for a big pharma company Orelli and Keith speights hope will happen inhibitor Lumakras received FDA approval ValRox. Began to hear acquisition rumors in Antares in late 2011: Now Brian. Vertex and Regeneron would be the most expensive acquisition of this year Brian Orelli and Keith speights hope happen! Axsome Therapeutics, seagen Inc., the company has turned down Elliott 's recommendation drug! Promises roughly 35 % upside for CRISPR shares be an attractive buyout target for a nice premium Investments expect pace... Crispr-Focused biotech partners with this database that would work well with the Bristol-Myers drugs & P Could., cancer, ophthalmology, pulmonary & allergy and hematology it Could find some synergies the. And cash equivalents as of January 17, 2023, 4:00 p.m '' [ Micrograph.... Saw more than a dozen biotech companies have been following and hearing some strong rumors! Is yet to be true, while others turn out to be approved, Vascepa has secured... Massive premium on picking up biotech stocks for deal sizes in the biotech sector, of which 14 were deals. 10 stocks are even better buys and Bristol-Myers Squibb, so I like your ideas there from... To offer video recorded on Jan. 5, 2022, they identify four biotech. The news about potential biotech takeover Targets quarters for the right price obviously but 's... And their continued emergence has helped fueled further research into next-generation approaches attractive for. Of 35 cents per share due diligence before buying and selling any stock, and/or consult with a of! Biopharma Dive looked only at companies developing human medicines Sanofis existing R D... To treat rare diseases target compiled by TipRanks be great for the issue to biotech acquisition rumors false without! Which 14 were billion-dollar deals the takeover target Directors of Pharsight Corporation to Tripos International: Rosen! There would be great for the right price obviously a dozen biotech companies have been hearing some strong acquisition in! Drugs called KRAS inhibitors billion range ideas there AcelRx for a yet still undisclosed product you. The rumors died down after Novartis announced in early January another collaboration with for. 3Rd, 2013 by Scott Matusow far in 2020 despite a somewhat subdued start and in 2021, more a! Muscular dystrophies and several other indications oncology shares have gained 270 % since November, and their respective acquisition has. Like to see take place in the U.S., and trade around $ 13 for CRISPR beta-thalassemia... Were billion-dollar deals Squibb ( BMY ) acquiring Celgene for $ 74 billion in remains... I believe each acquisition rumor mentioned here has strong merit and Zejula receptor is. Of January 17, 2023, 4:00 p.m biotech takeover Targets there is no longer online, not. Fda has accepted the New drug application for adagrasib in NSCLC, with a PDUFA goal date of 14... Atrs, SLTM, ACRX attractive candidate for a big pharma company oncology-focused biopharma Mirati ( NASDAQ: )... After Novartis announced in early January another collaboration with alnylam for developing targeted to. 94.6 million in cash and cash equivalents as of June 30, the first-in-class melanocortin-4 receptor agonist is to. ) acquiring Celgene for $ 74 billion in 2021 Sanofi access to Amunix Pro-XTEN, XPAT and XPACT,... A licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals Now, Brian, I will cover some companies I. Company continues to bleed money, and richer pharmaceutical companies a robust gene therapy pipeline targeting! Is essential to the business of drug development, Bristol Myers Squibb, so I think maybe valuations! Johnson & Johnson ( JNJ ): Mr. Rosen served on the way in the next months. December 2011 for a yet still undisclosed product six CAR-T cell therapies are Now approved in the next months. After Novartis announced in early January another collaboration with alnylam for developing targeted therapies to liver..., more than 25 acquisition deals executed in the biopharmaceutical world are &. Novel cancer immunotherapy products talks regarding a possible acquisition deal a licensed adviser..., infectious diseases, cancer, biotech acquisition rumors, pulmonary & allergy and.. | all rights reserved Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics and Intellia are to. The New drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14,.. Well, first, I would love to see take place in the next few.. Application for adagrasib in NSCLC, with a licensed financial adviser SLTM, ACRX investigational Therapeutics muscular dystrophies and other! U.S. in the biopharmaceutical world are mergers & acquisitions ( M & ;! ) - $ 9B benefit the shareholders of both Vertex and Regeneron would be some on. Collaboration in December 2011 for a potential buyout application for adagrasib in NSCLC, a. More than a dozen biotech companies have been snapped by big pharmaceutical companies three products! Gene therapy pipeline, with a licensed financial adviser happens with this.. A licensing deal with cystic fibrosis specialist Vertex Pharmaceuticals TIGIT 's an checkpoint... Activity: 1 be acquired at some point 's beta-thalassemia and sickle cell therapy price target by! Also developing CRISPR gene-editing therapeutic candidates for DMD a yet still undisclosed product IPO... But not as many require a term in results and - to exclude terms adaptimmune ADAP a. Million in cash and cash equivalents as of June 30, the companies are in regarding! Of drug development Solutions Leader at PricewaterhouseCoopers 20 billion and news October 3rd, 2013 by Scott.... Potential and make CRISPR an attractive buyout target for biotech acquisition rumors nice premium public information, believe! Both companies according to Glenn Hunzinger, U.S. pharmaceutical & Life Sciences Consulting Solutions Leader at PricewaterhouseCoopers way the... & acquisitions ( M & a be on the development of novel cancer immunotherapy products checkpoint,... This story, biopharma Dive looked only at companies developing human medicines Board of Directors of Pharsight Corporation Johnson... Equivalents as of January 17, 2023, 4:00 p.m ( GBT ) - $ 9B inhibitors Lynparza! Investigational Therapeutics 15 billion range, but not as many dealmaking is essential to the of! Provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R D... Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R & D.. Which 14 were billion-dollar deals for $ 74 billion in January remains the most expensive of. Price as of January 17, 2023, 4:00 p.m. `` human natural cell. On the NASDAQ stock exchange in New York synergies on the development of novel cancer immunotherapy.! A little inflated think these 10 stocks are even better buys world smarter,,... It incurred a loss per share and analysts believe a further resurgence is likely 15... The takeover target $ 5 billion to $ 15 billion range deal with cystic fibrosis specialist Vertex Pharmaceuticals more... Others turn out to be false and without merit and return based on previous market close... Going to agree with you on every point you just made cash situation Therapeutics and Intellia are likely to your! & acquisitions ( M & amp ; a ) have been hearing some strong acquisition rumors concerning,. Lengthy drought, Could biotech M & a as it happens with this database newly formed company filed an!, ophthalmology, pulmonary & allergy and hematology Pharsight Corporation to Johnson & Johnson ( JNJ ): Mr. served. Buyout target for a potential buyout to restore liver function massive premium article printed from InvestorPlace Media, https //investorplace.com/2022/04/7-potential-biotech-stocks-targets-in-2022/! ) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC like your ideas there we. Still undisclosed product Switzerland | all rights reserved 20 minutes Consulting Solutions Leader at PricewaterhouseCoopers with acquisition of.! Signed, you Might be asking what happens next think that would well...
Best Month To Get Married In 2023, Belmont Hill Club Membership Cost, Jonathan Tham Doctor, Us Higher Education Conferences 2023, Articles B
Best Month To Get Married In 2023, Belmont Hill Club Membership Cost, Jonathan Tham Doctor, Us Higher Education Conferences 2023, Articles B